Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05057468
PHASE3

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Sponsor: Assiut University

View on ClinicalTrials.gov

Summary

the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.

Official title: Cyclosporine As a Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-10-20

Completion Date

2026-11-30

Last Updated

2025-03-20

Healthy Volunteers

No

Interventions

DRUG

Cyclosporine

2.5-5 mg orally for 3 months

DRUG

Rituximab

375 mg/ m2 weekly dose for a maximum of 4 weeks

Locations (2)

Assiut university hospital

Asyut, Asyut Governorate, Egypt

Assiut university hospital

Asyut, Asyut Governorate, Egypt